98%
921
2 minutes
20
Dextran-based gels bearing two types of pendant N, N-dimethyl-N-alkyl-N-(2-hydroxypropyl) ammonium chloride groups with different alkyl chain length substituents (C and C/C, respectively) at the quaternary nitrogen were synthesized and structural characteristics of the compounds were studied by elemental analysis, potentiometric titration, FTIR and NMR spectroscopy. The morphology and size of polymeric microspheres were examined by SEM and their swelling behavior in water was also investigated. The hydrogels were evaluated as sorbents for sodium cholate (NaCA) and sodium deoxycholate (NaDCA) in water and 10 mM NaCl solutions. Different isotherm models (nearest-neighbor-interaction, Langmuir, Freundlich, Dubinin-Raduskevich, Sips and Hill) were used to elucidate the adsorption mechanism and established the characteristics of the most efficient polymeric sorbent. The maximum adsorption capacity of the gels was highly controlled by gel hydrophobicity which enhanced gel-bile salt affinity but decreased binding cooperativity. Swelling porosity, ionic strength and ligand lipophilicity were other factors that also affected the adsorption process. The hydrogel having 25 mol% pendant dodecyl groups retained the maximum amount of bile salts (1051 mg NaCA/g and 1138 mg NaDCA/g). All hydrophobically modified hydrogels revealed a better affinity and strength of binding compared to commercial Cholestyramine®.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2021.08.205 | DOI Listing |
Med Sci (Paris)
September 2025
Service des maladies de l'appareil digestif. Centre de compétence Maladies rares « Maladies inflammatoires des voies biliaires et hépatites autoimmunes », Hôpital Huriez, Lille, France.
Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC.
View Article and Find Full Text PDFFood Sci Biotechnol
October 2025
School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, 310023 Zhejiang China.
Unlabelled: Lactose intolerance is defined as the inability to digest lactose due to insufficient activity of the β-galactosidase enzyme, which catalyzes the hydrolysis of lactose into glucose and galactose. This study evaluated the potential probiotic properties of isolated S8, which exhibiting high β-galactosidase activity. The strain demonstrated higher survival rate under gastrointestinal stress, with 80% and 63% viability after 3 h in simulated gastric fluid and 8 h in intestinal fluid, respectively, while retaining 60.
View Article and Find Full Text PDFEnviron Microbiol Rep
October 2025
Reference Center for Lactobacilli (CERELA-CONICET), San Miguel de Tucumán, Argentina.
Limosilactobacillus fermentum CRL2085, isolated from feedlot cattle rations, displayed high efficiency as a probiotic when administered to animals. A comprehensive genomic analysis was performed to elucidate the genetic basis underlying its probiotic potential. Fifteen genomic islands and CRISPR-Cas elements were identified in its genome.
View Article and Find Full Text PDFAPMIS
September 2025
Department of Molecular Biology and Genetics, Tokat Gaziosmanpasa University, Tokat, Türkiye.
Pyroptosis is a lytic and pro-inflammatory regulated cell death pathway mediated by pores formed by the oligomerization of gasdermin proteins on cellular membranes. Different pro-inflammatory molecules such as interleukin-18 are released from these pores, promoting inflammation. Pyroptotic cell death has been implicated in many pathological conditions, including cancer and liver diseases.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon, United States of America.
The farnesoid X receptor (FXR), expressed in the liver and in the small intestine, is a key regulator of glucose and lipid metabolism. Its pharmacological modulation is explored as a potential treatment for obesity-related metabolic impairments. To develop effective pharmacological interventions, it is crucial to differentiate the individual contributions of intestinal and hepatic FXR to lipid metabolism.
View Article and Find Full Text PDF